NIVABUPA Niva Bupa Health Insurance Company Q2 FY26 results (Jul–Sep 2025) and concall
Niva Bupa Health reported a strong H1 FY26 with significant growth in profitability and premiums, led by its retail segment. The management was particularly bullish on the recent GST reduction to 0%, which has already resulted in a dramatic uptick in demand in October. The company has made a strategic decision to pass on the entire GST-related commission impact to distributors, confident that increased volumes and higher ticket sizes will more than compensate, positioning it for accelerated growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 19.2%, net profit down 369.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 1,321 | 1,258 | 1,671 | 1,932 | 1,574 +19% |
| EBITDA | -66 | -24 | 251 | 98 | -53 +20% |
| Net profit | 13 | 13 | 206 | 71 | -35 −369% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
